In this study, prior to treatment, clinical BPH patients exhibited significantly higher urinary levels of TAC, PGE2, IL-1β, and IL-6 compared to controls, supporting the concept of an elevated oxidative and inflammatory state in this patient population. The gene discussed is IL6; the disease is benign prostatic hyperplasia.